4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT; SPECTRA shows +10.8 BCVA gain, 61% treatment-burden reduction

4D Molecular Therapeutics announced first patient enrollments in the global Phase 3 4SIGHT trial of 4D-150 for DME and reported 2-year SPECTRA data showing clinical activity and reduced treatment burden.Key Highlights:Original SEC Filing: 4D Molecular Therapeutics, Inc. [ FDMT ] - 8-K - Sep. 28, 20…